Prolong Pharmaceuticals, LLC (the Company), a clinical-stage biopharmaceutical company, today announced that it will present key clinical data from HEMERA-1, its Phase 1/2 clinical trial in Acute ...
Zacks Investment Research on MSN
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia Therapeutics NTLA has made meaningful progress with the development of its in vivo programs. The company is currently advancing two late-stage in vivo candidates — lonvo-z (or, NTLA-2002) for ...
Patients with sickle cell disease and beta-thalassemia treated with exagamglogene autotemcel reported substantial and ...
The Nation UAE on MSN
Meeting mulls improving thalassemia prevention, bone marrow transplants
A meeting was held on Tuesday under the chairmanship of Federal Health Minister Mustafa Kamal to discuss strategies for preventing thalassemia and making bone marrow transplants more accessible to ...
Scientists have uncovered a toxic alliance between Aβ and fibrinogen that may explain how Alzheimer’s disease begins. The two ...
Everyday Health on MSN
New Blood Test to Rule Out Alzheimer’s Gets FDA Clearance
The FDA has cleared Elecsys pTau181, the first blood test for use in primary care to help rule out Alzheimer’s disease in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback